Dr Stephanie Bewick

Company: Destiny Pharma

Job title: Chief Business Officer

Seminars:

Introduction to NTCD-M3 10:00 am

• Highly statistically significant results in Phase 2 sets it apart from competitors • NTCD-M3 is a single strain so facilitates manufacture and low cost of goods • Being prepared for Phase 3 • Expected market positioning • Introduction to SPOR-COV • What it is and development plansRead more

day: Day Two